-
-
20/06/2024 21/06/2024 America/Toronto Biosimilars & Innovator Biologics Biosimilars & Innovator Biologics
June 20 – 21, 2024
New York City Bar Association, New York, NY
Please visit https://www.americanconference.com/biosimilars/ for more information and updates. New York City Bar Association, New York, NY true DD/MM/YYYY 1440 use-title -
-
-
20/06/2024 21/06/2024 America/Toronto Biosimilars & Innovator Biologics Biosimilars & Innovator Biologics
June 20 – 21, 2024
New York City Bar Association, New York, NY
Please visit https://www.americanconference.com/biosimilars/ for more information and updates. New York City Bar Association, New York, NY true DD/MM/YYYY 1440 use-title -
Reviewing Cases and Distilling Trends: The Key Federal and District Court Lawsuits Shaping the BPCIA Landscape
Larry Coury
Vice-President, Associate General Counsel
Regeneron Pharmaceuticals
Aziz Burgy
Partner
Axinn, Veltron & Harkrider LLP
Hassen A. Sayeed
Partner
O’Melveny & Myers LLP
Alison Hanstead
Partner
White & Case LLP
- Diving deep into Regeneron’s BPCIA litigation against Celltrion, Samsung Bioepis, Formycon, and Mylan for each of their proposed biosimilars of EYLEA
- Exploring Regeneron’s motion to establish multi-district litigation encompassing the aflibercept BPCIA cases
- Learning the latest biologic patent litigation strategies:
- Timing the lawsuit and seeking preliminary injunctions to block accused infringer’s at risk launch
- Learning the latest biosimilar patent litigation strategies:
- Appreciating when and how courts find permanent injunctions appropriate before receiving FDA approval
- Analyzing the decision to argue against a PI versus not launching at the end of the market exclusivity period